研究等業績 - 原著論文 - 三島 和夫
-
Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode.
Kazuhisa Yoshizawa, Masahiro Takeshima, Sayaka Ishino, Masaya Ogasawara, Dai Fujiwara, Yu Itoh, Aya Imanishi, Hidenobu Ohta, Kazuo Mishima
Neuropsychiatric disease and treatment ( DOVE MEDICAL PRESS LTD ) 17 2955 - 2963 2021年 [査読有り]
研究論文（学術雑誌） 国内共著
Purpose: A major depressive episode is a risk factor for venous thromboembolism (VTE) in psychiatric inpatients. However, it is unclear whether the severity of depressive symptoms or duration of the current depressive episode is associated with VTE. Further, the VTE prevalence among hospitalized patients with a major depressive episode receiving electroconvulsive therapy is unknown. This retrospective study examined factors associated with VTE among hospitalized patients with a major depressive episode and estimated the prevalence of VTE in such patients who underwent electroconvulsive therapy. Patients and Methods: Patients with a major depressive episode hospitalized in the Department of Neuropsychiatry at Akita University Hospital between January 2018 and December 2020 were included. Data from the first week of hospitalization were extracted from medical records. VTE was diagnosed based on the findings of computed tomography. To evaluate whether the severity of depressive symptoms or duration of the current depressive episode was associated with VTE, logistic regression analysis was conducted after adjusting for covariates with known VTE risk factors (antidepressants, antipsychotics, and physical comorbidities). Results: We analyzed 133 patients; of these, 14 were diagnosed with asymptomatic VTE. The severity of depressive symptoms (odds ratio: 1.220, 95% confidence interval: 1.081-1.377, p = 0.001) was significantly associated with VTE. The prevalence of VTE among those receiving electroconvulsive therapy was 35% (7/20). Conclusion: The prevalence of VTE was 35% among patients receiving in-hospital electroconvulsive therapy for a major depressive episode. VTE should be considered for hospitalized patients with severe depressive symptoms and patients receiving in-hospital electroconvulsive therapy for a major depressive episode.
-
The Usefulness of the Combination of D-Dimer and Soluble Fibrin Monomer Complex for Diagnosis of Venous Thromboembolism in Psychiatric Practice: A Prospective Study.
Masahiro Takeshima, Hiroyasu Ishikawa, Masaya Ogasawara, Munehiro Komatsu, Dai Fujiwara, Yu Itoh, Yuki Wada, Yuki Omori, Hidenobu Ohta, Kazuo Mishima
Vascular health and risk management ( DOVE MEDICAL PRESS LTD ) 17 239 - 246 2021年 [査読有り]
研究論文（学術雑誌） 国内共著
Purpose: D-dimer has the advantage of excluding venous thromboembolism (VTE) due to its high sensitivity but is disadvantageous for diagnosing VTE due to its low specificity. A method to increase the usefulness of D-dimer in the diagnosis of VTE is warranted. This study aimed to investigate the usefulness of the combination of D-dimer and soluble fibrin monomer complex (SFMC), which has been suggested as a new candidate marker for VTE, in VTE diagnosis. Patients and Methods: This prospective study in 109 subjects was performed at a psychiatric department between August 1, 2017 and December 31, 2019. Subjects' levels of D-dimer and SFMC were measured simultaneously. Plasma levels of D-dimer and SFMC were measured using NANOPIA® D-dimer and NANOPIA® SF. Subjects with positive D-dimer (≥1.0 µg/mL) results underwent contrast computed tomography for confirmation of VTE within 12 hours of D-dimer measurement. A receiver operating characteristic curve analysis was performed to examine the usefulness of SFMC for the diagnosis of VTE. Results: Only 109 of the 783 subjects without symptoms suggestive of VTE participated in the study. Out of 41 subjects with positive D-dimer results, 17 subjects were diagnosed with VTE. A receiver operating characteristic curve analysis was performed to determine cutoff values. The area under the curves was 0.848 for SFMC (p<0.001, 95% CI 0.722 to 0.974), and the optimal cutoff value was 10.0 µg/mL (sensitivity 58.8%, specificity 100%, positive predictive value 100%, negative predictive value 77.4%). Conclusion: SFMC was useful for diagnosing VTE in the psychiatric patients with positive D-dimer results.
-
Ishizuya A.
Scientific Reports ( Scientific Reports ) 11 ( 1 ) 2020年12月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Imanishi A.
Orphanet Journal of Rare Diseases ( Orphanet Journal of Rare Diseases ) 15 ( 1 ) 2020年09月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Yuge K.
BMC Psychiatry ( BMC Psychiatry ) 20 ( 1 ) 2020年09月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Kishi T.
Journal of clinical psychopharmacology ( Journal of clinical psychopharmacology ) 40 ( 5 ) 468 - 474 2020年09月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Yuya Takahashi, Sho Shindo, Takashi Kanbayashi, Masahiro Takeshima, Aya Imanishi, Kazuo Mishima
Neuropsychopharmacology reports ( Wiley ) 40 ( 1 ) 10 - 15 2020年03月 [査読有り]
研究論文（学術雑誌） 国内共著
We examined whether symptoms of dementia are improved by olfactory nerve stimulation in Alzheimer type dementia patients. First, a stick-type olfactory identification ability test was performed in patients with Alzheimer type dementia, to select patients without olfactory dysfunctions. Then, these patients were randomly assigned into the intervention (n = 19) and the control groups (n = 17). To evaluate the effects of olfactory nerve stimulation, we exposed the intervention group to a disinfecting ethanol with added aroma extracts from ceder and the control group to the ethanol without the added aroma extracts. Each group underwent the intervention for 8 weeks, cognitive and behavioral functions were evaluated before and after treatments using the Neuropsychiatric Inventory (NPI), the Japanese version of Zarit Caregiver Burden interview (J-ZBI), and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). A significant improvement was observed in the NPI score and J-ZBI in the intervention group compared to the control group at 4 and 8 weeks. On the other hand, there was no significant difference in the score of ADAS-cog. Exposure to cedar fragrance improved behavioral and psychological symptoms of dementia (BPSD) in Alzheimer type dementia and may reduce the burden of nursing care. In addition to its effectiveness, the procedure is simple and minimally invasive and would be a valuable non-pharmaceutical treatment.
-
Tracking intermediate performance of vigilant attention using multiple eye metrics
Takashi Abe, Kazuo Mishima, Shingo Kitamura, Akiko Hida, Yuichi Inoue, Koh Mizuno, Kosuke Kaida, Kyoko Nakazaki, Yuki Motomura, Kazushi Maruo, Toshiko Ohta, Satoshi Furukawa, David F Dinges, Katsuhiko Ogata
Sleep ( Oxford University Press (OUP) ) 43 ( 3 ) 2020年03月 [査読有り]
研究論文（学術雑誌） 国内共著
<title>Abstract</title>
Vigilance deficits account for a substantial number of accidents and errors. Current techniques to detect vigilance impairment measure only the most severe level evident in eyelid closure and falling asleep, which is often too late to avoid an accident or error. The present study sought to identify ocular biometrics of intermediate impairment of vigilance and develop a new technique that could detect a range of deficits in vigilant attention (VA). Sixteen healthy adults performed well-validated Psychomotor Vigilance Test (PVT) for tracking vigilance attention while undergoing simultaneous recording of eye metrics every 2 hours during 38 hours of continuous wakefulness. A novel marker was found that measured VA when the eyes were open—the prevalence of microsaccades. Notably, the prevalence of microsaccades decreased in response to sleep deprivation and time-on-task. In addition, a novel algorithm for detecting multilevel VA was developed, which estimated performance on the PVT by integrating the novel marker with other eye-related indices. The novel algorithm also tracked changes in intermediate level of VA (specific reaction times in the PVT, i.e. 300–500 ms) during prolonged time-on-task and sleep deprivation, which had not been tracked previously by conventional techniques. The implication of the findings is that this novel algorithm, named “eye-metrical estimation version of the PVT: PVT-E,” can be used to reduce human-error-related accidents caused by vigilance impairment even when its level is intermediate. -
Examination of the influence of cedar fragrance on cognitive function and behavioral and psychological symptoms of dementia in Alzheimer type dementia.
Takahashi Y, Shindo S, Kanbayashi T, Takeshima M, Imanishi A, Mishima K.
Neuropsychopharmacol Rep. 9 ( 10 ) 12096 2020年02月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan.
Miidera H, Enomoto M, Kitamura S, Tachimori H, Mishima K.
Diabetes Care 12 ( 10 ) dc19-1175 2020年02月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Tracking intermediate performance of vigilant attention using multiple eye metrics.
Abe T, Mishima K, Kitamura S, Hida A, Inoue Y, Mizuno K, Kaida K, Nakazaki K, Motomura Y, Maruo K, Ohta T, Furukawa S, Dinges DF, Ogata K.
Sleep 43 5733056 2020年02月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Kishi T.
Molecular Psychiatry ( Molecular Psychiatry ) 2020年 [査読有り]
研究論文（学術雑誌） 国内共著
-
Prevalence of asymptomatic venous thromboembolism in depressive inpatients
Takeshima M.
Neuropsychiatric Disease and Treatment ( Neuropsychiatric Disease and Treatment ) 16 579 - 587 2020年 [査読有り]
研究論文（学術雑誌） 国内共著
-
Kishi T.
Psychological Medicine ( Psychological Medicine ) 2020年 [査読有り]
研究論文（学術雑誌） 国内共著
-
Yoshimura M.
Biological Rhythm Research ( Biological Rhythm Research ) 2020年 [査読有り]
研究論文（学術雑誌） 国内共著
-
Long-term use of hypnotics: Analysis of trends and risk factors.
Enomoto M, Kitamura S, Tachimori H, Takeshima M, Mishima K.
Gen Hosp Psychiatry 62 49 - 55 2019年12月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Miyagawa T.
Journal of Human Genetics ( Journal of Human Genetics ) 64 ( 12 ) 1219 - 1225 2019年12月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis.
Takaesu Y, Utsumi T, Okajima I, Shimura A, Kotorii N, Kuriyama K, Yamashita H, Suzuki M, Watanabe N, Mishima K.
Sleep Med Rev. 48 101214 2019年10月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Oya K.
Neuropsychopharmacology Reports ( Neuropsychopharmacology Reports ) 39 ( 3 ) 241 - 246 2019年09月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Brexpiprazole as adjunctive treatment for major depressive disorder following treatment failure with at least one antidepressant in the current episode: a systematic review and meta-analysis.
Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N.
Int J Neuropsychopharmacol. 27 5539907 2019年07月 [査読有り]
研究論文（学術雑誌） 国内共著